Track 89bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

89bio, Inc. ETNB · Stock Open 89bio, Inc. in new tab

14.84 USD
EPS
-3.69
P/B
4.22
ROE
-86.86
Beta
1.26
Target Price
30.38 USD
Loading chart...
Key Metrics
Earnings dateNov. 6, 2025
EPS-3.69
Book Value3.52
Price to Book4.22
Debt/Equity7.21
% Insiders0.595%
Estimates
Forward P/E-6.35
Forward EPS-2.87
Target Mean Price30.38

DCF valuation

Model fair value for 89bio, Inc. (ETNB)
Result
Sign in to run the valuation for ETNB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 30.38 USD (low 14.50, high 55.00)
Low 14.50
Mean 30.38
High 55.00
Price 14.84
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

89bio, Inc. Logo 89bio, Inc. Analysis (ETNB)

United States Health Care Official Website Stock

Is 89bio, Inc. a good investment? 89bio, Inc. (ETNB) is currently trading at 14.84 USD. Market analysts have a consensus price target of 30.38 USD. This suggests a potential upside from current levels.

Earnings Schedule: 89bio, Inc. is expected to release its next earnings report on Nov. 6, 2025. The market consensus estimate for Forward EPS is -2.87.

Investor FAQ

Does 89bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is 89bio, Inc.?

89bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 6, 2025. The company currently has a trailing EPS of -3.69.

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.

Exchange Ticker
NMS (United States) ETNB
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion